Title : ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial.

Pub. Date : 2020

PMID : 33093947






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) is accepted as the international standard first-line regimen, but improvement in first line treatment is needed. Cyclophosphamide DNA damage inducible transcript 3 Homo sapiens